Centrus Energy (LEU) Q2 2026 earnings review
Surging Backlog vs. Near-Term GAAP Pain
Centrus delivered a highly complex quarter. Revenue jumped 14% YoY to $176.1M, driven entirely by a sudden $53.4M surge in Uranium sales that masked a steep 23% volume decline in the core SWU business. GAAP Net Income collapsed 42% YoY to $16.8M as the company absorbs massive non-capitalizable expansion costs and stock compensation. However, the long-term thesis strengthened considerably: total backlog surged to $4.5 billion, and the company officially signed its $900M HALEU award. Management is intentionally sacrificing near-term GAAP profitability to fund a once-in-a-generation manufacturing build-out.
🐂 Bull Case
Total backlog spiked to $4.5 billion (from $3.9B in Q1). Contingent LEU and HALEU sales commitments jumped to $3.0 billion, signaling immense pent-up commercial demand waiting for Centrus's capacity to come online.
The operational timeline is accelerating. Centrus raised its hiring guidance for Piketon to 175 net new employees and confirmed the first new Oak Ridge centrifuge will be completed by year-end 2026.
🐻 Bear Case
A massive red flag in the Technical Solutions segment: The DOE does not intend to exercise further options for the HALEU cascade operation, and the 2027 budget excludes funding for it, putting $0.8B of backlog in jeopardy.
Advanced technology costs grew by $7.5M and SG&A spiked by $12.8M (largely stock-comp withholding). Until these expansion costs become capitalizable, GAAP earnings will look structurally depressed.
⚖️ Verdict: ⚪
Neutral/Bullish. The near-term financials are messy due to contract lumpiness and expansion costs, and the DOE HALEU ops defunding is a legitimate concern. However, the $4.5B backlog and signed $900M HALEU award confirm the structural, multi-year growth thesis is intact.
Key Themes
DOE HALEU Operations Funding Deficit
Management disclosed a severe risk to the Technical Solutions backlog: The current DOE budget for FY27 does not include funding for the operation of the existing HALEU cascade, and the DOE communicated it does not intend to exercise further options. This puts approximately $0.8 billion of the segment's backlog at risk and immediately impacted Q2, driving TS segment gross profit to a loss of $1.7M.
Unprecedented Backlog Expansion
Total backlog expanded massively to $4.5 billion, extending to 2040. Crucially, the contingent LEU and HALEU sales commitments grew to $3.0 billion (up from $2.4B in Q1). $2.4 billion of this is already under definitive agreements, de-risking the future revenue pipeline for the Piketon facility expansion.
SWU Volume Contraction
Despite a massive LEU revenue beat ($153.4M), Separative Work Units (SWU) revenue actually decreased by $25.7 million. This was driven by a steep 23% YoY decline in SWU volume sold. While average pricing increased by 3%, the volume drop is a structural headwind that was only papered over this quarter by opportunistic uranium sales.
First-of-a-Kind Commercial HALEU Prepayments
Centrus signed its first large-scale commercial HALEU supply agreement that potentially includes prepayments. This is a vital evolution: it proves the company can secure non-dilutive, direct private capital from off-takers, reducing its sheer reliance on government funding structures.
Macro Tailwinds: Structural Supply Deficit
CEO Amir Vexler noted upward pressure on SWU prices continues, driven by healthy demand momentum and constrained supply. As Russian enrichment phases out of the Western market, Centrus stands as the only publicly-traded domestic alternative, structurally supporting price realization over the next decade.
Other KPIs
Uranium sales exploded from $0 in Q2 2025 (and $3M in Q1 2026) to $53.4M this quarter. Because Centrus's contract structures are highly lumpy, this opportunistic sale single-handedly drove the 14% consolidated revenue growth and masked the weakness in core SWU volumes.
While GAAP Net Income fell 42% to $16.8M, Adjusted Net Income (which strips out non-capitalizable Growth Costs and stock-based compensation) actually grew from $34.5M to $38.7M. The divergence highlights the heavy, near-term P&L toll of scaling up the Oak Ridge and Piketon facilities.
Slightly down from $1.96B at year-end 2025, but still a massive 'war chest'. This allows Centrus to execute its $350M-$500M FY26 capital deployment plan without needing to access equity markets during the initial, high-risk phase of the manufacturing build-out.
Guidance
Stable. The company maintained the upward-revised range it set in Q1. The $475M midpoint implies roughly 6% growth vs FY25's $448.7M. Given they have already generated $252.8M in H1, achieving this requires a lower run-rate of ~$222M in H2, assuming no massive delivery delays.
Stable. Reaffirmed aggressive spending targets for the industrial build-out. Through H1 2026, CapEx was only $94.8M, meaning capital deployment will drastically accelerate in H2 2026 as centrifuge manufacturing scales.
Accelerating. Raised significantly from the previous guidance of 100 net new employees. Management clearly sees operational readiness constraints and is front-loading talent acquisition to de-risk the Piketon expansion timeline.
Key Questions
DOE Funding Cliff Resolution
With the DOE communicating it does not intend to exercise further options for the HALEU cascade, what is the strategy to preserve the $0.8B Technical Solutions backlog? Will this cascade sit idle in 2027, or are commercial prepayments expected to fill the gap?
SWU Volume Pressures
SWU volumes dropped 23% year-over-year. Is this purely related to lumpy contract timing, or are customers delaying deliveries in anticipation of new capacity?
Uranium Sales Sustainability
Uranium sales provided a massive $53.4M revenue injection this quarter. How much inventory remains available for opportunistic selling, and is this run-rate repeatable in the second half of 2026?
Timeline for Capitalizing Growth Costs
Advanced Technology costs continue to weigh heavily on GAAP margins. At what specific milestone in the Oak Ridge or Piketon build-out will these Growth Costs transition to being capitalized on the balance sheet?